Advertisement
Advertisement

ACRV

ACRV logo

Acrivon Therapeutics Inc

7.38
USD
+0.17
+2.36%
Dec 18, 13:20 UTC -5
Open

Acrivon Therapeutics Inc Profile

About

Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics. The company's lead candidate includes ACR-368. Acrivon Therapeutics Inc. is based in WATERTOWN, Mass.

Info & Links

CEO

Peter Blume-Jensen

Headquarters

480 ARSENAL WAY, SUITE 100
WATERTOWN, MA 02472, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.acrivon.com

Auditor

PricewaterhouseCoopers LLP

Share holders

7

Employees

61

Acrivon Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

229.81M

Enterprise Value

186.40M

Enterprise Value/EBITDA(ttm)

-2.12

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.11

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-47.95%

Return on Invested Capital(ttm)

-51.25%

Return on Assets(ttm)

-43.73%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-88.01M

Net Income Available to Common(ttm)

-76.98M

Diluted EPS(ttm)

-2.70

Share Statistics

Beta (5Y Monthly)

0.55

52-Week Change

40.84%

S&P 500 52-Week Change

27.86%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

31.14M

Dividend Yield

0.00%

Float4

28.49M

% Held by Insiders

8.50%

% Held by Institutions

71.62%

Balance Sheet

Total Cash(mrq)

187.45M

Total Cash Per Share(mrq)

6.02

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.75%

Quick Ratio(mrq)

12.75%

Book Value Per Share(mrq)

6.32

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.27

Free Cash Flow(ytd)

-50.25M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement